STOCK TITAN
  1. Home
  2. REDIF

Redhill Biopharm (REDIF) Stock Price, News & Analysis

REDIF
Published by Stock Titan Data refreshed

What Changed

Company Description

This page collects what Stock Titan holds for REDIF, including price data and latest news.

Stock Performance

Chart
$—
-
-
Last updated:
-
Performance 1 year
-
Market Cap
352.7M
Shares outstanding

Latest News

View All
—

RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results

earnings
—

RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares

offering
—

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients

clinical trial covid-19
—

RedHill Biopharma Presents New Talicia® and Movantik® Data Analyses at ACG 2021

—

RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034

—

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo

—

RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval

clinical trial covid-19
—

RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021

conferences earnings date
—

RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study

clinical trial covid-19
—

RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021

conferences earnings date

Redhill Biopharm has 10 recent news articles. Key topics include earnings, offering, clinical trial, covid-19, conferences. View all REDIF news →

SEC Filings

View All

No SEC filings available for REDIF.